Advertisement

Topics

Latest "Biothera Pharmaceuticals, Inc." News Stories

21:36 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Biothera Pharmaceuticals, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Biothera Pharmaceuticals, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biothera Pharmaceuticals, Inc. for you to read. Along with our medical data and news we also list Biothera Pharmaceuticals, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biothera Pharmaceuticals, Inc. Companies for you to search.

Showing "Biothera Pharmaceuticals" News Articles 1–25 of 9,700+

Thursday 21st February 2019

Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com


$OPNT #FAIL Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa https://globenewswire.com/news-release/2019/02/21/1739815/0/en/Opiant-Pharmaceuticals-Announces-Top-line-Results-from-Phase-2-Clinical-Trial-of-OPNT001-fo

$OPNT #FAIL Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa https://globenewswire.com/news-release/2019/02/21/1739815/0/en/Opiant-Pharmaceuticals-Announces-Top-line-Results-from-Phase-2-Clinical-Trial-of-OPNT001-for-Treatment-of-Bulimia-Nervosa.html …

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the ...


Premier Inc. Projects 3.8 Percent Price Inflation for Pharmaceuticals

Strategic contracting capabilities outperform last year’s estimate Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released its inflation estimates for contracted and non-contracted pharmaceutical pricing for fiscal year 2020 (July 2019 – June 2020), projecting a 3.8 percent increase in total pharmaceutical costs. This ...

Cerevel Therapeutics Taps Otsuka’s Sanchez for Chief Medical Officer

Raymond Sanchez has been appointed chief medical officer of Cerevel Therapeutics. Sanchez comes to Boston-based Cerevel from Otsuka Pharmaceutical Development and Commercialization, where he most recently served as senior vice president, global clinical development. During the last half of his 11-year tenure at Otsuka, he was also chief medical officer of Otsuka subsidiary Avanir Pharmaceuticals. ...

Flinn Foundation Program Tops $1M in Funding Support with Selection of Six Arizona Bioscience Startup Firms

The Flinn Foundation has surpassed $1 million in funding support to benefit Arizona bioscience startup companies with the selection of six firms to participate in the foundation’s 2019 Bioscience Entrepreneurship Program. The Flinn Foundation has selected 34 Arizona bioscience firms since 2014 to participate in the program, which was crea...

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical trial, an open-label, single-arm study in subjects with Prostate Carcinoma. LMIS 25 mg is a 3-month depot injection. The primary efficacy end point was achieved in ...

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Immediate Availability of AP Rated Prochlorperazine Edisylate 10mg/2mL Injection Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home...

Catalyst defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for its high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigatio...

ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a....

Reminder: Ligand to Host Analyst Day on March 12th in New York City

Event to feature business updates and presentations by four corporate partners Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City. Company presenters will include John Higgins, CEO, Matt Foehr, C...

EU measures in support of generic pharmaceuticals producers

The EU is adopting new rules which should boost the competitiveness of EU producers of generic medicines and biosimilar products... The post EU measures in support of generic pharmaceuticals producers appeared first on

Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2018 financial results and provide a business update. Indiv...

Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call ...

Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New York Palace, New York, NY. The presentation will be webcast ...

Dicerna Bolsters Leadership Team to Support Continued Growth

— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigatio...

Innovus Pharma Announces Regulatory Filings by its International Distribution Partner, Lavasta Pharma, for ProstaGorx® in Certain Gulf Countries

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s a...

$ACHN Expands Operations and Clinical Development into Philadelphia Area Office Market https://finance.yahoo.com/news/achillion-pharmaceuticals-expands-operations-clinical-110000624.html …

$ACHN Expands Operations and Clinical Development into Philadelphia Area Office Market https://finance.yahoo.com/news/achillion-pharmaceuticals-expands-operations-clinical-110000624.html …

Teva settles 'pay-to-delay' case with FTC

Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving the firm’s subsidiary Cephalon. The settlement comes after Teva was made to pay the FTC $1.2 billion over so-called ‘pay-to-delay’ policies in which the firm was accused of participating in blocking the entry of generic drugs into the market by rec...

Avara Avlon falls into administration putting 270 Bristol jobs at risk

Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk. The contract development and manufacturing organisation (CDMO) is hoping to sell facilities in Avonmouth a suburb of Bristol, which it bought from AstraZeneca in 2016. read more

Catalyst defends drug price after Bernie Sanders' rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

Rigaku Presents Latest XRM and CT Technology at 2019 TSM Meeting

Rigaku to showcase its newest X-ray imaging analytical instrumentation at the 54th Meeting of the Texas Society for Microscopy SAN ANTONIO (PRWEB) February 21, 2019 X-ray analytical instrument manufacturer Rigaku Corporation is pleased to announce its attendance at the 54th annual meeting of the Texas Society for Microscopy (TSM). The event is hosted by the Kleberg Advanced Microscopy Center at T...

Dermapharm continues to drive development of new products

DGAP-News: Dermapharm Holding SE / Key word(s): Product Launch 21.02.2019 / 07:30 The issuer is solely responsible for the content of this announcement. Dermapharm continues to drive development of new products New products for the treatment of acute hay fever symptoms open up significant market potential bite away(R) successful in all distribution channels and receives award as on...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks